SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma reports 11% fall in Q4 consolidated net profit

22 May 2025 Evaluate

Mankind Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2025.

The company has reported 18.28% decline in its net profit at Rs 382.46 crore for the quarter under review as compared to Rs 468.02 crore for the same quarter in the previous year. However, total income of the company increased by 12.11% at Rs 2,345.91 crore for Q4FY25 as compared to Rs 2,092.43 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 10.90% decline in its net profit at Rs 424.65 crore for fourth quarter ended March 31, 2025 as compared to Rs 476.59 crore for the same quarter in the previous year. However, total income of the company increased by 32.47% at Rs 3,330.70 crore for Q4FY25 as compared to Rs 2,514.39 crore for the corresponding quarter previous year.

For the year ended March 31, 2025, the company has reported 3.69% rise in its net profit at Rs 1,945.48 crore as compared to Rs 1,876.16 crore for the previous year. The total income of the company increased by 12.26% at Rs 9,991.01 crore for year under review as compared to Rs 8,899.75 crore for year ended March 31, 2024.

For the year ended March 31, 2025, on the consolidated basis, the company has reported 3.57% rise in its net profit at Rs 2,011.12 crore as compared to Rs 1,941.77 crore for the previous year. The total income of the company increased by 20.91% at Rs 12,744.23 crore for year under review as compared to Rs 10,540.66 crore for year ended March 31, 2024.

Mankind Pharma Share Price

2187.50 43.90 (2.05%)
21-Apr-2026 11:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.20
Dr. Reddys Lab 1219.35
Cipla 1231.50
Zydus Lifesciences 927.85
Lupin 2321.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×